Ex-GSK Leader Launches ‘Molecular Clamp’ Vaccine Company Vicebio

Will Begin RSV Studies In 2023

 
• By Andrew McConaghie

Venture capital firm Medicxi has chosen Emmanuel Hanon to lead the company, hiring two more ex-GSK veterans to create what they hope is a ‘dream team’ in vaccines.

RSV
Vicebio will begin its Phase I study in respiratory syncytial virus in the second half of 2023. • Source: Shutterstock

More from Business

More from Scrip